RLN2 and chronic kidney disease: Therefore, we speculate that therapeutic administration of relaxin-2 mRNA has potential for suppressing the progression of chronic kidney disease (CKD) in patients, since many of the pathomechanisms seen in the UUO model also appear in patients with progressive CKD [34,35].